{"7BG.F": {"short_name": "BERGENBIO ASA", "long_name": "BerGenBio ASA", "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Norway", "city": "Bergen"}, "7UM.F": {"short_name": "ULTIMOVACS AS  DK1", "long_name": "Ultimovacs ASA", "summary": "Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company engages in performing a clinical development program with clinical trials in Europe and the United States. Its lead product candidate is UV1, a peptide-based vaccine, which completed Phase I clinical trial that induces T cell response against the universal cancer antigen telomerase. The company was founded in 2011 and is headquartered in Oslo, Norway.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Norway", "city": "Oslo"}, "8NN.F": {"short_name": "NORDIC NANOVECTOR NK 0,20", "long_name": "Nordic Nanovector ASA", "summary": "Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for haematological cancers. The company's lead product candidate is Betalutin, an antibody-radionuclide-conjugate, which has completed Phase I/IIa clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChemBio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Norway", "city": "Oslo"}, "B4V.F": {"short_name": "ARCTICZYMES TECH ASA NK 1", "long_name": "ArcticZymes Technologies ASA", "summary": "ArcticZymes Technologies ASA develops, manufactures, and markets immunomodulating beta-glucans and recombinant enzymes in Norway, Europe, Asia, Australia, Africa, and the Americas. It operates through two segments, Enzymes and Beta-Glucans. The company provides recombinant enzymes that are primarily derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics, and therapeutics. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of DNA from RNA samples; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company also provides immunomodulating beta-glucans products for the wound care, animal and consumer health, and adjuvants markets. It offers Woulgan wound gel; M-Glucan, a natural immune-stimulating product for fish and animal feed; and M-Gard, a natural immune-stimulating ingredients to enhance physical health. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Troms\u00c3\u00b8, Norway.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Norway", "city": "Troms\u00c3\u00b8"}, "BGBIO.OL": {"short_name": "BERGENBIO ASA", "long_name": "BerGenBio ASA", "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.", "currency": "NOK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "OSL", "market": "no_market", "country": "Norway", "city": "Bergen"}, "BRRGF": {"short_name": "BERGENBIO ASA", "long_name": "BerGenBio ASA", "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Norway", "city": "Bergen"}, "EXTX.OL": {"short_name": "EXACT THERAPEUTICS", "long_name": "EXACT Therapeutics AS", "summary": "EXACT Therapeutics AS, a clinical stage biotech company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology (chemotherapy and immunotherapy), infectious diseases, and neurological conditions. EXACT Therapeutics AS has a collaboration with GE Healthcare to develop an ultrasound probe to be used in studies using acoustic cluster therapy across various disease conditions. The company was founded in 2012 and is based in Oslo, Norway.", "currency": "NOK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "OSL", "market": "no_market", "country": "Norway", "city": "Oslo"}, "HBC.OL": {"short_name": "HOFSETH BIOCARE AS", "long_name": "Hofseth BioCare ASA", "summary": "Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for the human nutrition, and pet and feed markets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company has a research agreement with Stanford University School of Medicine to investigate the gastro-intestinal-protective properties of HBC's salmon protein hydrolysate peptides in children and adults with GI tract disorders. The company was founded in 2000 and is headquartered in \u00c3\u0085lesund, Norway.", "currency": "NOK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "OSL", "market": "no_market", "country": "Norway", "city": "\u00c3\u0085lesund"}, "HBQ.F": {"short_name": "HOFSETH BIOCARE  NK 0,01", "long_name": "Hofseth BioCare ASA", "summary": "Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for the human nutrition, and pet and feed markets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company has a research agreement with Stanford University School of Medicine to investigate the gastro-intestinal-protective properties of HBC's salmon protein hydrolysate peptides in children and adults with GI tract disorders. The company was founded in 2000 and is headquartered in \u00c3\u0085lesund, Norway.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Norway", "city": "\u00c3\u0085lesund"}, "HOFBF": {"short_name": "HOFSETH BIOCARE AS", "long_name": "Hofseth BioCare ASA", "summary": "Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for the human nutrition, and pet and feed markets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company has a research agreement with Stanford University School of Medicine to investigate the gastro-intestinal-protective properties of HBC's salmon protein hydrolysate peptides in children and adults with GI tract disorders. The company was founded in 2000 and is headquartered in \u00c3\u0085lesund, Norway.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Norway", "city": "\u00c3\u0085lesund"}, "PCIB.OL": {"short_name": "PCI BIOTECH HLDG", "long_name": "PCI Biotech Holding ASA", "summary": "PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's lead product candidate is Amphinex, a photosensitiser fimaporfin. Its PCI technology is applied to three distinct anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer, which in Phase Ib clinical study in bile duct cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination; and fimaNAc, a nucleic acid therapeutics delivery technology. The company has collaborative research programs with AstraZeneca, Bavarian Nordic, BioNTech, eTheRNA immunotherapies, IMV, and Phio Pharmaceuticals. PCI Biotech Holding ASA is headquartered in Oslo, Norway.", "currency": "NOK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "OSL", "market": "no_market", "country": "Norway", "city": "Oslo"}, "SOFTX.OL": {"short_name": "SOFTOX SOLUTIONS", "long_name": "SoftOx Solutions AS", "summary": "SoftOx Solutions AS, together with its subsidiaries, operates as a medtech company in Norway. Its SoftOx technology kills the microorganisms in biofilms by acting on various microbial components. The company engages in the development of SoftOx Wound Irrigation Solution that is under preclinical studies for the prevention and treatment of infections on breached or compromised skin, including acute wounds and skin lesions in patients with eczema; and SoftOx Biofilm Eradicator, which is in preclinical studies to treat biofilm infections in non-healing chronic wounds. The company was founded in 2012 and is headquartered in Oslo, Norway.", "currency": "NOK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "OSL", "market": "no_market", "country": "Norway", "city": "Oslo"}, "TA5.F": {"short_name": "TARGOVAX ASA  NK -,10", "long_name": "Targovax ASA", "summary": "Targovax ASA, a clinical stage immuno-oncology company, engages in the development of oncolytic viruses to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102 that is in Phase I/II clinical studies for the treatment of mesothelioma, melanoma, peritoneal disease, and prostate cancer. It also develops neoantigen cancer vaccines targeting tumors with oncogenic RAS\u00c2\u0096mutations. The company has collaboration agreements with Cancer Research Institute, Ludwig Cancer Research, and AstraZeneca to develop ONCOS-102 for peritoneal disease; Sotio to develop ONCOS-102 for prostate cancer; Valo Therapeutics to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Merck & Co., Inc. to evaluate ONCOS-102 in combination with KEYTRUDA in mesothelioma. Targovax ASA is based in Oslo, Norway.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Norway", "city": "Oslo"}, "TRVX.OL": {"short_name": "TARGOVAX ASA", "long_name": "Targovax ASA", "summary": "Targovax ASA, a clinical stage immuno-oncology company, engages in the development of oncolytic viruses to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102 that is in Phase I/II clinical studies for the treatment of mesothelioma, melanoma, peritoneal disease, and prostate cancer. It also develops neoantigen cancer vaccines targeting tumors with oncogenic RAS\u00c2\u0096mutations. The company has collaboration agreements with Cancer Research Institute, Ludwig Cancer Research, and AstraZeneca to develop ONCOS-102 for peritoneal disease; Sotio to develop ONCOS-102 for prostate cancer; Valo Therapeutics to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Merck & Co., Inc. to evaluate ONCOS-102 in combination with KEYTRUDA in mesothelioma. Targovax ASA is based in Oslo, Norway.", "currency": "NOK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "OSL", "market": "no_market", "country": "Norway", "city": "Oslo"}, "VACC.OL": {"short_name": "VACCIBODY AS", "long_name": "Vaccibody AS", "summary": "Vaccibody AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of melanoma, lung, head and neck, renal, and bladder; and VB10.16, a therapeutic DNA vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. The company has clinical collaboration agreements with Roche and Nektar Therapeutics. Vaccibody AS was founded in 2007 and is based in Oslo, Norway.", "currency": "NOK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "OSL", "market": "no_market", "country": "Norway", "city": "Oslo"}}